Novel human nucleic acid molecules and polypeptides encoding a novel human ion channel expressed in spinal cord and brain
CA 2436941 A1 · Owner: Bristol-Myers Squibb Company · Inventors: Gaughan, Glen; Ramanathan, Chandra; Feder, John
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to novel human nucleic acid molecules encoding novel human cation channels, and proteins and polypeptides encoded by such nucleic acid molecules. More specifically the nucleic acid molecules of the , invention include novel human genes e.g. hVR1d.1 and hVR1d.2, that encode proteins or polypeptides that are expressed in spinal cord and brain tissues and display sequence homology and structural homology to the vanilloid and TRP (transient receptor potential) families of cation channel proteins. The proteins and polypeptides of the invention directed to this novel human cation channel may be therapeutically valuable targets for drug delivery in the …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 30, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 30, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 30, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.